Definition and clinical significance of the MGUS-like phenotype in patients with monoclonal gammopathies

The Multiple Myeloma Hub was pleased to speak with steering committee member, Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is the definition and clinical significance of the monoclonal gammopathy of undetermined significance (MGUS)–like phenotype in patients with monoclonal gammopathies?

In this presentation, Paiva summarizes a recent publication¹ and discusses the current lack of standardized methods to identify the subgroup of patients with multiple myeloma and light-chain (AL) amyloidosis who have MGUS-like phenotype. He goes on to outline the flow cytometry-based tool that was developed to address this issue and provides the key data it produced with a focus on progression-free and overall survival outcomes. Paiva concludes with the clinical applications of this tool and discusses how these data can help subdivide groups of patients to inform a more individualized treatment approach.